Ginkgo Bioworks Holdings Inc vs Tripadvisor Inc Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.4 (market cap $505.73M), while Tripadvisor Inc Common Stock trades at $10.63 (market cap $1.28B). The key difference: Tripadvisor Inc Common Stock is far larger — about 2.5× Ginkgo Bioworks Holdings Inc's market cap. Which is the better fit depends on your goals.
| DNA | TRIP | |
|---|---|---|
Market Cap | $505.73M | $1.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $19.14 |
52-Week Low | $5.48 | $9.24 |
Enterprise Value | $607.68M | $1.33B |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
Tripadvisor (TRIP) trades at $10.59, down 1.76% on the day, with a bearish technical signal and recent earnings misses. The company reported Q2 2026 EPS of $0.35, below the $0.42 estimate (Zacks Investment Research, 2026-08-06). Revenue was $1.89B in 2025, with net income improving to $40M. Analyst consensus is a $13.29 price target, but sentiment is mixed with 62.5% hold ratings. The sale of TheFork for $700M provides cash but highlights competitive pressures from AI travel tools.
The outlook is cautious; while valuation ratios like P/S of 0.72 appear attractive, weak profitability and competitive threats from AI-driven platforms pose significant risks. Near-term catalysts include TheFork sale proceeds and Viator's performance, but investor sentiment remains neutral amid earnings volatility and macro headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →